CTSD and proximal spinal muscular atrophy: Subsequently, in Shorling’s study, after identifying CTSD as a potential biomarker, a validation analysis was performed in a larger cohort of 31 treated SMA pediatric patients (12 type 1, 9 type 2, 6 type 3, and 4 presymptomatically treated SMA subjects).